Panchsheel Organics FY26 Profit Down 21.48% to ₹10.83 Cr, Recommends ₹0.80 Dividend

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Panchsheel Organics FY26 Profit Down 21.48% to ₹10.83 Cr, Recommends ₹0.80 Dividend
Overview

Panchsheel Organics reported a 21.48% decline in net profit to ₹10.83 crore for FY26, with revenue slightly down. The company recommended a final dividend of ₹0.80 per share.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Panchsheel Organics Reports FY26 Profit Decline, Recommends Dividend

Net profit for FY2025-26: ₹10.83 crore
Revenue from operations FY2025-26: ₹106.78 crore

Reader Takeaway: Profitability pressure despite stable revenue; dividend payout offers shareholder return.

What just happened

Panchsheel Organics Limited announced its financial results for the fiscal year ended March 31, 2026. The company reported revenue from operations of ₹106.78 crore, a marginal decrease of 0.37% from ₹107.18 crore in the previous fiscal year. Net profit saw a more significant decline of 21.48%, falling to ₹10.83 crore from ₹13.79 crore in FY 2024-25. Earnings per share (EPS) also decreased by 21.49% to ₹8.22.

For the fourth quarter ended March 31, 2026, the company posted revenue of ₹31.07 crore and a net profit of ₹1.70 crore.

Why this matters

The decline in profitability, despite relatively stable revenues, indicates pressure on margins or increased costs. For investors, this profit contraction is a key point of concern. However, the board's recommendation of a final dividend of ₹0.80 per share provides a positive aspect, signaling a return of capital to shareholders.

The backstory

Panchsheel Organics operates in the manufacturing and trading of bulk drugs and intermediates. The company's financial performance is typically influenced by raw material costs, regulatory environments, and demand from pharmaceutical companies.

What changes now

Investors will be looking for management's commentary on the reasons behind the profit decline and strategies to improve margins in the future. The dividend payout, subject to shareholder approval, will offer some immediate return.

Risks to watch

The primary risk is the sustained pressure on profitability. Investors should monitor cost management and pricing power in the competitive bulk drug market.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

  • Revenue: ₹106.78 crore in FY26 vs ₹107.18 crore in FY25.
  • Net Profit: ₹10.83 crore in FY26 vs ₹13.79 crore in FY25.
  • Dividend: ₹0.80 per share recommended for FY26.

What to track next

Investors should track the company's performance in the upcoming quarters, focusing on revenue growth, margin improvement, and any management insights into the profitability challenges. The record date for the dividend is June 12, 2026.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.